1214899-85-0

Basic information

• Product Name: 6-bromo-1-methyl-1H-indazol-3-amine
• Synonyms: 6-bromo-1-methyl-1H-indazol-3-amine;3-Amino-6-bromo-1-methyl-1H-indazole
• CAS NO: 1214899-85-0
• Molecular Formula: C₈H₈BrN₃
• Molecular Weight: 226.07322
• Mol File: 1214899-85-0.mol

Chemical Properties

• Boiling Point: 378.443 °C at 760 mmHg
• Flash Point: 182.676 °C
• Appearance: /
• Density: 1.763 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.12±0.50(Predicted)
• CAS DataBase Reference: 6-bromo-1-methyl-1H-indazol-3-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-1-methyl-1H-indazol-3-amine(1214899-85-0)
• EPA Substance Registry System: 6-bromo-1-methyl-1H-indazol-3-amine(1214899-85-0)

Safety Data

• Hazardous Substances Data: 1214899-85-0(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
6-Bromo-1-methyl-1H-indazol-3-amine is used as a key intermediate in the synthesis of various biologically active compounds for medicinal applications, leveraging its unique structural features to enhance the potency and selectivity of resulting pharmaceuticals.
Used in Pharmaceutical Drug Development:
6-Bromo-1-methyl-1H-indazol-3-amine serves as a building block in the development of new pharmaceutical drugs, particularly those targeting cancer and microbial infections, due to its potential to contribute to the creation of effective and novel therapeutic agents.
Used in Anticancer Research:
6-Bromo-1-methyl-1H-indazol-3-amine is used as a precursor in the design and synthesis of potential anticancer agents, aiming to develop drugs that can target and combat cancer cells more effectively.
Used in Antimicrobial Research:
6-Bromo-1-methyl-1H-indazol-3-amine is also utilized in antimicrobial research, where it is employed to create new agents capable of combating resistant strains of bacteria and other pathogens, contributing to the fight against antibiotic resistance.
Used in Organic Synthesis:
6-Bromo-1-methyl-1H-indazol-3-amine is used as a versatile reagent in organic synthesis, enabling the creation of a wide range of chemical products and intermediates for various applications in the chemical industry.
Used in Drug Discovery:
In the field of drug discovery, 6-Bromo-1-methyl-1H-indazol-3-amine is used to explore new chemical entities with potential therapeutic benefits, contributing to the advancement of medical treatments and healthcare solutions.

Upstream product

• 105942-08-3 4-bromo-6-fluorobenzonitrile 
• 60-34-4 methylhydrazine 
• 404827-77-6 ethyl 3-(3-(cyclopropanecarboxamido)-1H-indazol-6-yl)benzoate 
• 74-88-4 methyl iodide 

Downstream Products

• 1429869-67-9 5-[3-(6-bromo-1-methyl-1H-indazol-3-ylamino)-phenyl]-5-methyl-morpholin-3-one 

Relevant articles and documents

ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR

The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19

The Mediator complex-associated cyclin-dependent kinase CDK8 has been implicated in human disease, particularly in colorectal cancer where it has been reported as a putative oncogene. Here we report the discovery of 109 (CCT251921), a potent, selective, and orally bioavailable inhibitor of CDK8 with equipotent affinity for CDK19. We describe a structure-based design approach leading to the discovery of a 3,4,5-trisubstituted-2-aminopyridine series and present the application of physicochemical property analyses to successfully reduce in vivo metabolic clearance, minimize transporter-mediated biliary elimination while maintaining acceptable aqueous solubility. Compound 109 affords the optimal compromise of in vitro biochemical, pharmacokinetic, and physicochemical properties and is suitable for progression to animal models of cancer.

HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.

AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS

The present invention relates to novel aminoindazolyl derivative compounds of Formula (I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7, to compositions containing said derivatives and processes for their preparation.

A general, one-step synthesis of substituted indazoles using a flow reactor

Flow chemistry is a rapidly emerging technology within the pharmaceutical industry, both within medicinal and development chemistry groups. The advantages of flow chemistry, increased safety, improved reproducibility, enhanced scalability, are readily apparent, and we aimed to exploit this technology in order to provide small amounts of pharmaceutically interesting fragments via a safe and scalable route, which would enable the rapid synthesis of multigram quantities on demand. Here we report a general and versatile route which utilises flow chemistry to deliver a range of known and novel indazoles, including 3-amino and 3-hydroxy analogues.

COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.